The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

SAN FRANCISCO -- At least 400 researchers, physicians, activists, and other concerned citizens gathered here Monday night to ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...